Kitov Pharmaceuticals accounted it plans to apply for listing on the NASDAQ exchange, joining Israel-based Teva and Kamada that are traded on Wall Street.

Kitov is hoping for approval from the U.S. Food and Drug Administration (FDA) after its Phase III clinical trial of a combination drug for the treatment of hypertension and pain relief.

Advertisement

The drug has a potential market of $10 billion, and the company’s stock in Israel has climbed almost 10-fold this year.

It also is developing a combination drug for the treatment of osteoarthritis, with the risk of hypertension and other side effects associated with current treatments, Globes reported.

Advertisement

1 COMMENT

  1. Israel has more NASDAQ companies than Europe. That's why they will eventually back off on their settlement kick, circumcision ban, and ritual slaughter ban. Europe needs Israel's technological development more than Israel needs Europe.

Comments are closed.

Loading Facebook Comments ...